In this study, we are reporting the preclinical evaluation of an Auger-emitting radio-brominated PARP-1 inhibitor, [77Br]Br-WC-DZ, in prostate cancer cell lines and in vivo models. Here, PARP1 is linked to prostate carcinoma.